Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

September 23, 2023

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

September 15, 2023

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

September 14, 2023

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

September 5, 2023

Ascendis Pharma Reports Second Quarter 2023 Financial Results

September 5, 2023

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

September 5, 2023

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

August 24, 2023

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

August 15, 2023

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

June 17, 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

June 13, 2023

Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 27

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© September 2023 Ascendis Pharma